Welcome to our dedicated page for Nkarta news (Ticker: NKTX), a resource for investors and traders seeking the latest updates and insights on Nkarta stock.
Nkarta, Inc. reports developments as a clinical-stage biotechnology company developing allogeneic, off-the-shelf engineered natural killer (NK) cell therapies for autoimmune diseases. Company updates center on NKX019, an investigational CAR-NK cell therapy for B cell-mediated autoimmune diseases, and on the Ntrust-1 and Ntrust-2 clinical studies.
Recurring news themes include FDA protocol discussions, outpatient dosing plans, dose-escalation updates, B-cell depletion data, preclinical and clinical presentations, quarterly financial results, cash runway commentary, workforce and operating updates, and participation in healthcare and investor conferences.
Nkarta, Inc. (Nasdaq: NKTX) will participate in the Cantor Virtual Global Healthcare Conference on September 15, 2020, with a fireside chat presentation scheduled for 2:00 p.m. ET. The event will feature a live audio webcast available on Nkarta's website, with a replay archived for approximately four weeks.
Nkarta is focused on developing engineered natural killer (NK) cell therapies for cancer, utilizing a proprietary platform for efficient manufacturing and cell engineering aimed at enhancing tumor targeting and persistence.
Nkarta, Inc. (Nasdaq: NKTX) reported its Q2 2020 financial results, highlighting significant progress despite COVID-19 challenges. The company completed an IPO on July 14, 2020, raising $289.8 million and has cash and equivalents of $341.8 million as of June 30, 2020, sufficient to fund operations into late 2023.
NKX101 is set to enter Phase 1 trials in Q4 2020, with plans to file for NKX019 in Q1 2021. R&D expenses were $7.9 million, with a net loss of $51.1 million for the quarter. Financial guidance estimates cash reserves will range between $300 million and $310 million by year-end.
Nkarta, Inc. (Nasdaq: NKTX) has priced its initial public offering at $18.00 per share, offering 14,000,000 shares and expecting gross proceeds of approximately $252.0 million. The shares began trading on the Nasdaq Global Select Market on July 10, 2020, with the offering anticipated to close on July 14, 2020. A 30-day option is available for underwriters to purchase an additional 2,100,000 shares at the offering price. The offering is managed by Cowen, Evercore ISI, Stifel, and Mizuho Securities.